Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes StudyGlobeNewsWire • 03/30/23
Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023GlobeNewsWire • 03/27/23
Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS DisordersGlobeNewsWire • 03/07/23
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGYGlobeNewsWire • 02/14/23
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target EngagementGlobeNewsWire • 01/09/23
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical MeetingsGlobeNewsWire • 12/08/22
Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 11/16/22
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor ModulatorGlobeNewsWire • 11/09/22
Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual MeetingGlobeNewsWire • 10/24/22
Trevena to Participate at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
Trevena, Inc's (TRVN) CEO Carrie Bourdow on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/13/22